Your browser doesn't support javascript.
loading
SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI).
Lundin, Magnus; Ferrannini, Giulia; Mellbin, Linda; Johansson, Isabelle; Norhammar, Anna; Näsman, Per; Shahim, Bahira; Smetana, Stina; Venkateshvaran, Ashwin; Wang, Anne; Sörensson, Peder; Rydén, Lars.
Afiliación
  • Lundin M; Department of Clinical Physiology, Karolinska Institutet, Stockholm, Sweden.
  • Ferrannini G; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Mellbin L; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
  • Johansson I; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Norhammar A; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Capio S:t Görans Hospital, Stockholm, Sweden.
  • Näsman P; Center for Safety Research, KTH Royal Institute of Technology, Stockholm, Sweden.
  • Shahim B; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
  • Smetana S; Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
  • Venkateshvaran A; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Wang A; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
  • Sörensson P; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
  • Rydén L; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. Electronic address: lars.ryden@ki.se.
Diabetes Res Clin Pract ; 193: 110141, 2022 Nov.
Article en En | MEDLINE | ID: mdl-36336088
AIMS/HYPOTHESIS: Established dysglycaemia (impaired glucose tolerance [IGT] or type 2 diabetes [T2DM]) is a risk factor for further cardiovascular events in patients with coronary artery disease. Sodium-glucose cotransporter 2 inhibitors reduce this risk. The aim of the present investigation was to test the hypothesis that empagliflozin exerts beneficial effects on myocardial function in patients with a recent acute coronary syndrome and newly detected dysglycaemia. METHODS: Forty-two patients (mean age 67.5 years, 81 % male) with recent myocardial infarction (n = 36) or unstable angina (n = 6) and newly detected IGT (n = 27) or T2DM (n = 15) were randomised to 25 mg of empagliflozin daily (n = 20) or placebo (n = 22) on top of ongoing therapy. They were investigated with oral glucose tolerance tests, stress-perfusion cardiac magnetic resonance imaging (CMR) and echocardiography at three occasions: before randomisation, after seven months on study drug and three months following cessation of such drug. Primary outcome was a change in left ventricular (LV) end-diastolic volume (LVEDV) and secondary outcomes were a change in a) systolic and diastolic LV function; b) coronary flow reserve; c) myocardial extracellular volume (ECV) in non-infarcted myocardium; d) aortic pulse wave velocity. RESULTS: Empagliflozin induced a significant decrease in fasting and post load glucose (p < 0.05) and body weight (p < 0.01). Empagliflozin did not influence LVEDV, LV systolic or mass indexes, coronary flow reserve, ECV or aortic pulse wave velocity. Echocardiographic indices of LV diastolic function (E/e' and mitral E/A ratio) were not influenced. No safety concerns were identified. CONCLUSIONS/INTERPRETATION: Empagliflozin had predicted effects on the dysglycaemia but did not influence variables expressing LV function, coronary flow reserve and ECV. An explanation may be that the LV function of the patients was within the normal range.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Intolerancia a la Glucosa / Diabetes Mellitus Tipo 2 / Infarto del Miocardio Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Diabetes Res Clin Pract Asunto de la revista: ENDOCRINOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Irlanda

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Intolerancia a la Glucosa / Diabetes Mellitus Tipo 2 / Infarto del Miocardio Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Diabetes Res Clin Pract Asunto de la revista: ENDOCRINOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Irlanda